Aclaris Therapeutics Inc
ACRS2.900USD
-0.170-5.54%
Market hours （ET）Quotes delayed by 15 min
314.19MMarket Cap
LossP/E TTM
More Details of Aclaris Therapeutics Inc Company
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. It has a multi-stage portfolio of drug candidates powered by a robust research and development engine. Its KINect drug discovery platform, combined with its preclinical development capabilities, allows it to identify and advance potential product candidates that it may develop independently or in collaboration with third parties. It has two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment is engaged in the provision of laboratory services. Its drug candidates include Bosakitug (ATI-045), ATI-2138 and ATI-052. Its other investigational product candidates include Lepzacitinib (ATI-1777) and Zunsemetinib (ATI-450).
Aclaris Therapeutics Inc Info
Ticker SymbolACRS
Company nameAclaris Therapeutics Inc
IPO dateOct 07, 2015
CEOWalker (Neal S)
Number of employees64
Security typeOrdinary Share
Fiscal year-endOct 07
Address701 Lee Road
CityWAYNE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19087
Phone14843247933
Websitehttps://www.aclaristx.com/
Ticker SymbolACRS
IPO dateOct 07, 2015
CEOWalker (Neal S)
Company Executives of Aclaris Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. James (Jim) Loerop
Mr. James (Jim) Loerop
Chief Business Officer
Chief Business Officer
103.31K
+21.18%
Mr. Christopher P. Molineaux
Mr. Christopher P. Molineaux
Lead Independent Director
Lead Independent Director
57.96K
+9.02%
Mr. William Douglas Humphries
Mr. William Douglas Humphries
Independent Director
Independent Director
33.52K
+16.68%
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Independent Director
Independent Director
21.75K
+28.26%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
17.32K
+38.27%
Dr. Andrew N. (Drew) Schiff, M.D.
Dr. Andrew N. (Drew) Schiff, M.D.
Independent Director
Independent Director
13.96K
+52.29%
Mr. Kevin Balthaser
Mr. Kevin Balthaser
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Neal S. Walker
Dr. Neal S. Walker
Non-Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Non-Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Hugh M. Davis, Ph.D.
Dr. Hugh M. Davis, Ph.D.
President, Chief Operating Officer, Director
President, Chief Operating Officer, Director
--
--
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. James (Jim) Loerop
Mr. James (Jim) Loerop
Chief Business Officer
Chief Business Officer
103.31K
+21.18%
Mr. Christopher P. Molineaux
Mr. Christopher P. Molineaux
Lead Independent Director
Lead Independent Director
57.96K
+9.02%
Mr. William Douglas Humphries
Mr. William Douglas Humphries
Independent Director
Independent Director
33.52K
+16.68%
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Independent Director
Independent Director
21.75K
+28.26%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
17.32K
+38.27%
Dr. Andrew N. (Drew) Schiff, M.D.
Dr. Andrew N. (Drew) Schiff, M.D.
Independent Director
Independent Director
13.96K
+52.29%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2018
By BusinessUSD
Name
Revenue
Proportion
Licensing
1.33M
75.13%
Laboratory Research Revenue
442.00K
24.87%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Licensing
1.33M
75.13%
Laboratory Research Revenue
442.00K
24.87%
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BML Capital Management LLC
13.15%
Vivo Capital, LLC
8.20%
The Vanguard Group, Inc.
6.01%
Adage Capital Management, L.P.
4.87%
BlackRock Institutional Trust Company, N.A.
4.74%
Other
63.02%
Shareholders
Shareholders
Proportion
BML Capital Management LLC
13.15%
Vivo Capital, LLC
8.20%
The Vanguard Group, Inc.
6.01%
Adage Capital Management, L.P.
4.87%
BlackRock Institutional Trust Company, N.A.
4.74%
Other
63.02%
Shareholder Types
Shareholders
Proportion
Investment Advisor
30.60%
Hedge Fund
18.68%
Venture Capital
13.38%
Investment Advisor/Hedge Fund
12.98%
Research Firm
4.55%
Individual Investor
2.71%
Pension Fund
0.27%
Bank and Trust
0.10%
Insurance Company
0.03%
Other
16.71%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
268
87.21M
107.82%
-1.36K
2025Q3
310
87.21M
125.17%
-6.19M
2025Q2
317
93.40M
125.33%
-2.09M
2025Q1
333
94.15M
124.07%
-40.17M
2024Q4
335
88.85M
102.21%
+24.75M
2024Q3
326
52.14M
151.10%
-2.43M
2024Q2
330
55.01M
154.79%
-1.68M
2024Q1
311
55.76M
163.32%
-60.07M
2023Q4
322
59.19M
127.84%
-16.13M
2023Q3
316
71.10M
117.87%
-2.18M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BML Capital Management LLC
14.25M
13.15%
--
--
Jun 30, 2025
Vivo Capital, LLC
8.89M
8.21%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
6.66M
6.15%
+1.69M
+34.04%
Jun 30, 2025
Adage Capital Management, L.P.
9.63M
8.89%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.95M
4.57%
+3.73M
+304.49%
Jun 30, 2025
Rock Springs Capital Management LP
4.77M
4.4%
-277.00K
-5.49%
Jun 30, 2025
Decheng Capital LLC
4.04M
3.73%
--
--
Jun 30, 2025
Morgan Stanley & Co. LLC
3.53M
3.26%
+1.12M
+46.64%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.46M
2.28%
+1.28M
+108.40%
Jun 30, 2025
D. E. Shaw & Co., L.P.
2.80M
2.58%
-144.23K
-4.90%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.7%
iShares Micro-Cap ETF
0.04%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Avantis US Small Cap Equity ETF
0.01%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.7%
iShares Micro-Cap ETF
Proportion0.04%
iShares Russell 2000 ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Aclaris Therapeutics Inc?
The top five shareholders of Aclaris Therapeutics Inc are:
BML Capital Management LLC holds 14.25M shares, accounting for 13.15% of the total shares.
Vivo Capital, LLC holds 8.89M shares, accounting for 8.21% of the total shares.
The Vanguard Group, Inc. holds 6.66M shares, accounting for 6.15% of the total shares.
Adage Capital Management, L.P. holds 9.63M shares, accounting for 8.89% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.95M shares, accounting for 4.57% of the total shares.
BML Capital Management LLC holds 14.25M shares, accounting for 13.15% of the total shares.
Vivo Capital, LLC holds 8.89M shares, accounting for 8.21% of the total shares.
The Vanguard Group, Inc. holds 6.66M shares, accounting for 6.15% of the total shares.
Adage Capital Management, L.P. holds 9.63M shares, accounting for 8.89% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.95M shares, accounting for 4.57% of the total shares.
What are the top three shareholder types of Aclaris Therapeutics Inc?
The top three shareholder types of Aclaris Therapeutics Inc are:
BML Capital Management LLC
Vivo Capital, LLC
The Vanguard Group, Inc.
BML Capital Management LLC
Vivo Capital, LLC
The Vanguard Group, Inc.
How many institutions hold shares of Aclaris Therapeutics Inc (ACRS)?
As of 2025Q4, 268 institutions hold shares of Aclaris Therapeutics Inc, with a combined market value of approximately 87.21M, accounting for 107.82% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -17.35%.
What is the biggest source of revenue for Aclaris Therapeutics Inc?
In FY2025Q2, the Licensing business generated the highest revenue for Aclaris Therapeutics Inc, amounting to 1.33M and accounting for 75.13% of total revenue.
